<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font19 { font-size : 19; } .font23 { font-size : 23; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; }</style>
 <body>
  <p>
   <span class="font30">the </span>
   <span class="font23">and </span>
   <span class="font19">with </span>
   <span class="font16">patients </span>
   <span class="font14">[]. </span>
   <span class="font14">COVID- </span>
   <span class="font13">infection </span>
   <span class="font12">may </span>
   <span class="font12">for </span>
   <span class="font12">immune </span>
   <span class="font12">SARS-CoV- </span>
   <span class="font12">multiple </span>
   <span class="font12">risk </span>
   <span class="font12">during </span>
   <span class="font12">cells </span>
   <span class="font12">have </span>
   <span class="font12">are </span>
   <span class="font12">vaccine </span>
   <span class="font11">against </span>
   <span class="font11">that </span>
   <span class="font11">viral </span>
   <span class="font11">treatment </span>
   <span class="font11">sclerosis </span>
   <span class="font11">future </span>
   <span class="font11">response </span>
   <span class="font11">impact </span>
   <span class="font11">not </span>
   <span class="font11">after </span>
   <span class="font11">been </span>
   <span class="font11">{background </span>
   <span class="font11">The </span>
   <span class="font11">but </span>
   <span class="font11">pandemic </span>
   <span class="font11">also </span>
   <span class="font11">this </span>
   <span class="font11">should </span>
   <span class="font11">compared </span>
   <span class="font11">exposure </span>
   <span class="font11">from </span>
   <span class="font11">lymphopenia </span>
   <span class="font11">phase </span>
   <span class="font11">severe </span>
   <span class="font11">vaccines </span>
   <span class="font11">has </span>
   <span class="font11">increase </span>
   <span class="font11">protein </span>
   <span class="font11">DMT </span>
   <span class="font11">patient </span>
   <span class="font11">taking </span>
   <span class="font10">effect </span>
   <span class="font10">margin </span>
   <span class="font10">who </span>
   <span class="font10">However, </span>
   <span class="font10">Scler </span>
   <span class="font10">can </span>
   <span class="font10">inactivated </span>
   <span class="font10">infections </span>
   <span class="font10">safe </span>
   <span class="font10">{border-style </span>
   <span class="font10">cases </span>
   <span class="font10">its </span>
   <span class="font10">susceptibility </span>
   <span class="font10">Accessed </span>
   <span class="font10">Disord </span>
   <span class="font10">alemtuzumab </span>
   <span class="font10">continue </span>
   <span class="font10">likely </span>
   <span class="font10">oral </span>
   <span class="font10">other </span>
   <span class="font10">potential </span>
   <span class="font10">px;} </span>
   <span class="font10">#ffffff;} </span>
   <span class="font10">Possible </span>
   <span class="font10">Relat </span>
   <span class="font10">agents </span>
   <span class="font10">intravenous </span>
   <span class="font10">ocrelizumab </span>
   <span class="font10">treated </span>
   <span class="font10">clinical </span>
   <span class="font10">protective </span>
   <span class="font10">two </span>
   <span class="font10">were </span>
   <span class="font10">%), </span>
   <span class="font10">May </span>
   <span class="font10">negative </span>
   <span class="font10">one </span>
   <span class="font10">reduce </span>
   <span class="font10">reported </span>
   <span class="font10">start </span>
   <span class="font10">storm </span>
   <span class="font10">was </span>
   <span class="font10">July </span>
   <span class="font10">cytokine </span>
   <span class="font10">infected </span>
   <span class="font10">influenza </span>
   <span class="font10">pandemic. </span>
   <span class="font10">DMTs </span>
   <span class="font10">case </span>
   <span class="font10">depletion </span>
   <span class="font10">each </span>
   <span class="font10">effects </span>
   <span class="font10">had </span>
   <span class="font10">humoral </span>
   <span class="font10">lymphocytes </span>
   <span class="font10">mild </span>
   <span class="font10">ALC </span>
   <span class="font10">Neurol </span>
   <span class="font10">Patients </span>
   <span class="font10">[prescribing </span>
   <span class="font10">both </span>
   <span class="font10">coronavirus </span>
   <span class="font10">higher </span>
   <span class="font10">infection. </span>
   <span class="font10">information]. </span>
   <span class="font10">natalizumab </span>
   <span class="font10">need </span>
   <span class="font10">route </span>
   <span class="font10">safer </span>
   <span class="font10">their </span>
   <span class="font10">therapies </span>
   <span class="font10">therapy </span>
   <span class="font10">Immune </span>
   <span class="font10">disease </span>
   <span class="font10">early </span>
   <span class="font10">fingolimod </span>
   <span class="font10">innate </span>
   <span class="font10">lymphocyte </span>
   <span class="font10">mitigation </span>
   <span class="font10">receiving </span>
   <span class="font10">relapsing </span>
   <span class="font10">some </span>
   <span class="font10">those </span>
   <span class="font10">when </span>
   <span class="font10">Mechanism </span>
   <span class="font10">Risk </span>
   <span class="font10">Side </span>
   <span class="font10">System </span>
   <span class="font10">This </span>
   <span class="font10">considered </span>
   <span class="font10">disease-modifying </span>
   <span class="font10">increases </span>
   <span class="font10">live </span>
   <span class="font10">more </span>
   <span class="font10">respiratory </span>
   <span class="font10">responses </span>
   <span class="font10">teriflunomide </span>
   <span class="font10">time </span>
   <span class="font10">without </span>
   <span class="font10">Action </span>
   <span class="font10">Effects </span>
   <span class="font10">III </span>
   <span class="font10">Impact </span>
   <span class="font10">Infectious </span>
   <span class="font10">Med </span>
   <span class="font10">Mitigation </span>
   <span class="font10">Pandemic </span>
   <span class="font10">Potential </span>
   <span class="font10">RMS </span>
   <span class="font10">Relevance </span>
   <span class="font10">Strategies </span>
   <span class="font10">Therefore, </span>
   <span class="font10">action </span>
   <span class="font10">administration </span>
   <span class="font10">approved </span>
   <span class="font10">double-blind, </span>
   <span class="font10">first </span>
   <span class="font10">highly </span>
   <span class="font10">placebo </span>
   <span class="font10">several </span>
   <span class="font10">similar </span>
   <span class="font10">study </span>
   <span class="font10">system </span>
   <span class="font10">than </span>
   <span class="font10">virus </span>
   <span class="font10">will </span>
   <span class="font10">Engl </span>
   <span class="font10">Multiple </span>
   <span class="font10">No, </span>
   <span class="font10">One </span>
   <span class="font10">active </span>
   <span class="font10">antibodies </span>
   <span class="font10">beneficial </span>
   <span class="font10">cladribine </span>
   <span class="font10">did </span>
   <span class="font10">dosing </span>
   <span class="font10">incidence </span>
   <span class="font10">including </span>
   <span class="font10">increased </span>
   <span class="font10">infectious </span>
   <span class="font10">less </span>
   <span class="font10">ongoing </span>
   <span class="font10">possible </span>
   <span class="font10">primary </span>
   <span class="font10">profile </span>
   <span class="font10">published </span>
   <span class="font10">px; </span>
   <span class="font10">randomized, </span>
   <span class="font10">related </span>
   <span class="font10">reports </span>
   <span class="font10">role </span>
   <span class="font10">trials </span>
   <span class="font10">vaccination </span>
   <span class="font10">{font-family </span>
   <span class="font10">Alemtuzumab </span>
   <span class="font10">B-cell </span>
   <span class="font10">Clin </span>
   <span class="font10">Consider </span>
   <span class="font10">Inc.; </span>
   <span class="font10">Not </span>
   <span class="font10">PPMS </span>
   <span class="font10">Unlikely </span>
   <span class="font10">additional </span>
   <span class="font10">agent </span>
   <span class="font10">all </span>
   <span class="font10">antibody </span>
   <span class="font10">cause </span>
   <span class="font10">cell </span>
   <span class="font10">cell-depleting </span>
   <span class="font10">cells. </span>
   <span class="font10">course </span>
   <span class="font10">efficacy </span>
   <span class="font10">even </span>
   <span class="font10">font-size </span>
   <span class="font10">hypogammaglobulinemia </span>
   <span class="font10">immunity </span>
   <span class="font10">inflammatory </span>
   <span class="font10">laboratory </span>
   <span class="font10">live-attenuated </span>
   <span class="font10">long-term </span>
   <span class="font10">mechanism </span>
   <span class="font10">most </span>
   <span class="font10">new </span>
   <span class="font10">ocrelizumab-treated </span>
   <span class="font10">outcome </span>
   <span class="font10">potency </span>
   <span class="font10">potent </span>
   <span class="font10">reconstitution </span>
   <span class="font10">risks </span>
   <span class="font10">these </span>
   <span class="font10">trial </span>
   <span class="font10">vector </span>
   <span class="font10">via </span>
   <span class="font10">well </span>
   <span class="font10">(MA): </span>
   <span class="font10">CNS </span>
   <span class="font10">Cladribine </span>
   <span class="font10">DMF </span>
   <span class="font10">For </span>
   <span class="font10">IFN-β </span>
   <span class="font10">IL-, </span>
   <span class="font10">Immunol </span>
   <span class="font10">Its </span>
   <span class="font10">Natalizumab </span>
   <span class="font10">Sclerosis </span>
   <span class="font10">T-cell </span>
   <span class="font10">There </span>
   <span class="font10">URTIs </span>
   <span class="font10">although </span>
   <span class="font10">antiviral </span>
   <span class="font10">cells, </span>
   <span class="font10">cellular </span>
   <span class="font10">compatibility </span>
   <span class="font10">daily </span>
   <span class="font10">despite </span>
   <span class="font10">develop </span>
   <span class="font10">diagnosed </span>
   <span class="font10">dimethyl </span>
   <span class="font10">double; </span>
   <span class="font10">fumarate </span>
   <span class="font10">herpes </span>
   <span class="font10">implicated </span>
   <span class="font10">increasing </span>
   <span class="font10">infections. </span>
   <span class="font10">infusions </span>
   <span class="font10">levels </span>
   <span class="font10">newly </span>
   <span class="font10">occurred </span>
   <span class="font10">only </span>
   <span class="font10">potentially </span>
   <span class="font10">preferred </span>
   <span class="font10">production </span>
   <span class="font10">progressive </span>
   <span class="font10">rare </span>
   <span class="font10">received </span>
   <span class="font10">reinfection </span>
   <span class="font10">relapses </span>
   <span class="font10">relatively </span>
   <span class="font10">safety </span>
   <span class="font10">sclerosisN </span>
   <span class="font10">serology </span>
   <span class="font10">side </span>
   <span class="font10">social </span>
   <span class="font10">strategies </span>
   <span class="font10">studies, </span>
   <span class="font10">syndrome </span>
   <span class="font10">there </span>
   <span class="font10">three </span>
   <span class="font10">unknown. </span>
   <span class="font10">unlikely </span>
   <span class="font10">vaccine. </span>
   <span class="font10">while </span>
   <span class="font10">Based </span>
   <span class="font10">Both </span>
   <span class="font10">Corporation; </span>
   <span class="font10">Neuroimmunol </span>
   <span class="font10">Ocrelizumab </span>
   <span class="font10">Safe </span>
   <span class="font10">Teriflunomide </span>
   <span class="font10">These </span>
   <span class="font10">[], </span>
   <span class="font10">accumulation </span>
   <span class="font10">acute </span>
   <span class="font10">al.COVID- </span>
   <span class="font10">anti-CD </span>
   <span class="font10">applicable. </span>
   <span class="font10">associated </span>
   <span class="font10">based </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">counts </span>
   <span class="font10">cytokines </span>
   <span class="font10">described </span>
   <span class="font10">does </span>
   <span class="font10">favorable </span>
   <span class="font10">found </span>
   <span class="font10">frequency </span>
   <span class="font10">further </span>
   <span class="font10">global </span>
   <span class="font10">group. </span>
   <span class="font10">high </span>
   <span class="font10">idiosyncratic </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">incompatible </span>
   <span class="font10">infusion </span>
   <span class="font10">interferon </span>
   <span class="font10">lesion </span>
   <span class="font10">low </span>
   <span class="font10">lymphopenia, </span>
   <span class="font10">management </span>
   <span class="font10">modulators </span>
   <span class="font10">monitoring </span>
   <span class="font10">monthly </span>
   <span class="font10">months </span>
   <span class="font10">neutralizing </span>
   <span class="font10">non-selective </span>
   <span class="font10">number </span>
   <span class="font10">outcomes </span>
   <span class="font10">patients. </span>
   <span class="font10">recent </span>
   <span class="font10">relevance </span>
   <span class="font10">require </span>
   <span class="font10">second </span>
   <span class="font10">serious </span>
   <span class="font10">solid; </span>
   <span class="font10">studies </span>
   <span class="font10">surface </span>
   <span class="font10">symptoms </span>
   <span class="font10">through </span>
   <span class="font10">type </span>
   <span class="font10">type- </span>
   <span class="font10">use </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(%) </span>
   <span class="font10">(NJ): </span>
   <span class="font10">Cambridge </span>
   <span class="font10">Fingolimod </span>
   <span class="font10">Glatiramer </span>
   <span class="font10">Incompatible </span>
   <span class="font10">JCV-IgG </span>
   <span class="font10">MS. </span>
   <span class="font10">March </span>
   <span class="font10">Neuroinflamme </span>
   <span class="font10">Some </span>
   <span class="font10">Two </span>
   <span class="font10">University </span>
   <span class="font10">Unknown </span>
   <span class="font10">about </span>
   <span class="font10">absolute </span>
   <span class="font10">addition, </span>
   <span class="font10">agents. </span>
   <span class="font10">among </span>
   <span class="font10">anti-inflammatory </span>
   <span class="font10">antigen-presenting </span>
   <span class="font10">any </span>
   <span class="font10">approach </span>
   <span class="font10">become </span>
   <span class="font10">benefit </span>
   <span class="font10">between </span>
   <span class="font10">bold </span>
   <span class="font10">causing </span>
   <span class="font10">cell-depletion </span>
   <span class="font10">certain </span>
   <span class="font10">common </span>
   <span class="font10">count </span>
   <span class="font10">courier; </span>
   <span class="font10">cycle </span>
   <span class="font10">deficiency </span>
   <span class="font10">dendritic </span>
   <span class="font10">development </span>
   <span class="font10">dose </span>
   <span class="font10">due </span>
   <span class="font10">em; </span>
   <span class="font10">especially </span>
   <span class="font10">extended </span>
   <span class="font10">fatal </span>
   <span class="font10">fumarates </span>
   <span class="font10">given </span>
   <span class="font10">grid.. </span>
   <span class="font10">herpetic </span>
   <span class="font10">high-risk </span>
   <span class="font10">hyperinflammatory </span>
   <span class="font10">important </span>
   <span class="font10">incidences </span>
   <span class="font10">include </span>
   <span class="font10">infection-related </span>
   <span class="font10">integrins </span>
   <span class="font10">interaction </span>
   <span class="font10">interval </span>
   <span class="font10">killer </span>
   <span class="font10">lead </span>
   <span class="font10">limited </span>
   <span class="font10">medication </span>
   <span class="font10">mentioned </span>
   <span class="font10">might </span>
   <span class="font10">modest </span>
   <span class="font10">myelin </span>
   <span class="font10">natural </span>
   <span class="font10">neutropenia </span>
   <span class="font10">over </span>
   <span class="font10">overall </span>
   <span class="font10">ozanimod </span>
   <span class="font10">perhaps </span>
   <span class="font10">placebo-controlled </span>
   <span class="font10">post-vaccination </span>
   <span class="font10">predictors </span>
   <span class="font10">pro-inflammatory </span>
   <span class="font10">prolonged </span>
   <span class="font10">proposed </span>
   <span class="font10">pt;} </span>
   <span class="font10">recommended </span>
   <span class="font10">reduction </span>
   <span class="font10">sclerosisJ </span>
   <span class="font10">secondary </span>
   <span class="font10">selective </span>
   <span class="font10">self-reported </span>
   <span class="font10">series </span>
   <span class="font10">shown </span>
   <span class="font10">subcutaneous </span>
   <span class="font10">they </span>
   <span class="font10">treatment. </span>
   <span class="font10">trials, </span>
   <span class="font10">which </span>
   <span class="font10">writing, </span>
  </p>
 </body>
</html>
